Healthbeacon plc, the leading digital therapeutics company that develops products for managing injectable medications for patients in the home, has today announced the launch of its new Smart Scale, an integrated solution that forms part of its Injection Care Management System (ICMS).
The HealthBeacon Smart Scale enables patients to add weight monitoring to its ICMS, as the connected weight scale tracks weight progression, providing clinical teams with insights on specific medication outcomes.
There are currently nine million patients in the U.S. that self-administer injectable medications in the home, and many require their weight to be carefully managed and monitored. HealthBeacon’s integrated Smart Scale will sync seamlessly with its ICMS, helping patients improve adherence to therapies and providing healthcare practitioners with access to important clinical data.
HealthBeacon provides each member of its injection care management system with a Smart Sharps Bin, a companion app, a more sustainable waste management service, and now, the integrated Smart Scale. This enhances a system that already improves the likelihood of success on therapy by increasing adherence by as much as 26% and persistence by 19% according to peer reviewed research.
It is expected that the HealthBeacon Smart Scale will become available to HealthBeacon patients this autumn.
Commenting, HealthBeacon CEO and co-founder, Jim Joyce, said: “The launch of the HB Smart Scale is an important step as we strive to improve injection adherence globally. Weight management is an important factor in the health of many patients that are required to self-administer injectable medications at home. This product integrates seamlessly into our technology which patients are already using, meaning this addition can improve their health with no added level of complexity.”
The announcement of the launch of HealthBeacon’s Smart Scale was made at the annual MAGIC conference in Chicago, the largest patient conference for children with growth disorders. The monitoring of weight progression is of particular importance to children suffering from growth disorders.
Commenting further, Mr Joyce said: “We know how difficult it is for families that must administer injections to their children at home. For children on growth hormones, it can be difficult to both manage injections and monitor growth progress. HealthBeacon’s Smart Scale will support affected families by enabling parents to track their child’s growth along with monitoring injection adherence. It also benefits children as they become teenagers and can administer medication themselves, providing them with a level of independence while enabling their parents to continue to monitor their adherence and track their growth.”